Clinical trials: Analgesics
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Pain
Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy
The primary objective of this study is to evaluate the analgesic efficacy of hydrocodone bitartrate/acetaminophen immediate-release tablets at doses of 5.0 milligrams (mg)/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg every 4 to 6…
- Trial name
- NCT02487108
- Testing
- TV-46763
- Where
- 8 sites in United States
- Volunteers
- 569 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pain
Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction
The purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen compared to placebo in moderate to severe pain following molar extraction.
- Trial name
- NCT00935311
- Testing
- ABT-712 Extended-release, Hydrocodone/Acetaminophen Immediate-release
- Where
- 3 sites in United States
- Volunteers
- 122 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Pain, Diabetic Neuropathy
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
- Trial name
- NCT00857623
- Testing
- AZD2066
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Fibromyalgia
A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability. This study assessed treatment differences in physical function as well as the improvements in overall subject status…
- Trial name
- NCT03056690
- Testing
- ASP0819
- Where
- 24 sites in United States
- Volunteers
- 186 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Knee Osteoarthritis, Pain Management
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
The purpose of the study is to compare magnitude of postsurgical analgesic effect in different groups following a single dose of study drug when administered via adductor canal block in subjects undergoing primary unilateral…
- Trial name
- NCT05139030
- Testing
- bupivacaine liposome injectable suspension, Bupivacaine Hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 167 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Neuralgia, Postherpetic
RN624 For Pain Of Post-Herpetic Neuralgia
This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
- Trial name
- NCT00568321
- Testing
- RN624
- Where
- 31 sites in United States
- Volunteers
- 99 people
- Sponsor
- Pfizer
Postoperative Pain
An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain
The primary objective of this study is to characterize the pharmacokinetics and pharmacodynamics of hydromorphone oral solution in pediatric subjects aged 28 days to 16 years inclusive.
- Trial name
- Palladone (NCT00465647)
- Testing
- Hydromorphone
- Where
- 14 sites in United States
- Volunteers
- 116 people
- Sponsor
- Purdue Pharma LP
Chronic Pain, Osteoarthritis
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee…
- Trial name
- NCT00982280
- Testing
- Tapentadol PR
- Where
- 24 sites in Australia, Denmark and 4 more
- Volunteers
- 82 people
- Sponsor
- Grünenthal GmbH
Post-operative Pain
Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study
The objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with Nurofen Plus® and Panadeine® Extra.
- Trial name
- NCT01229449
- Testing
- Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®
- Where
- United States
- Volunteers
- 678 people
- Sponsor
- Reckitt Benckiser LLC
Rheumatoid Arthritis
Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving pain associated with rheumatoid arthritis (RA) compared with placebo and naproxen (similar to Aleve®).
- Trial name
- NCT00626275
- Testing
- ADL5859, Naproxen
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Tumor, Pain
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
- Trial name
- NCT00472303
- Testing
- Tapentadol Extended Release, Morphine Sulphate Controlled Release
- Where
- 71 sites in Austria, Bulgaria and 14 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH
Fibromyalgia
A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability.
- Trial name
- NCT03092726
- Testing
- ASP8062
- Where
- 24 sites in United States
- Volunteers
- 183 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pain, Postoperative
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain
The objective of the study is to evaluate the efficacy and safety of a single oral dose of two dose combinations of naproxen sodium and diphenhydramine (DPH) to demonstrate that naproxen sodium/DPH combination provides added…
- Trial name
- Morpheus II (NCT01280591)
- Testing
- Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689)
- Where
- 2 sites in United States
- Volunteers
- 712 people
- Sponsor
- Bayer
Neoplasms
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid (morphine-like medications) analgesics (drug used to…
- Trial name
- NCT01309386
- Testing
- Tapentadol ER, Morphine SR
- Where
- 22 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Janssen Pharmaceutical K.K.
Arthritis, Osteoarthritis
Tanezumab In Osteoarthritis Of The Knee (2)
The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.
- Trial name
- NCT00830063
- Testing
- tanezumab 10 mg, tanezumab 5 mg, naproxen
- Where
- 94 sites in United States
- Volunteers
- 832 people
- Sponsor
- Pfizer
Osteoarthritis, Knee, Osteoarthritis, Hip
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of…
- Trial name
- NCT02697773
- Testing
- Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
- Where
- 87 sites in United States, Canada and 1 more
- Volunteers
- 698 people
- Sponsor
- Pfizer
Arthritis, Osteoarthritis
Tanezumab in Osteoarthritis Of The Hip
The purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients
- Conditions
- Arthritis, Osteoarthritis, Osteoarthritis, Hip
- Trial name
- NCT00744471
- Testing
- tanezumab
- Where
- 99 sites in United States
- Volunteers
- 627 people
- Sponsor
- Pfizer
Osteoarthritis, Rheumatoid Arthritis
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT01961271
- Testing
- Buprenorphine transdermal patch
- Where
- 16 sites in Hong Kong, Philippines and 1 more
- Volunteers
- 114 people
- Sponsor
- Mundipharma Pte Ltd.